Sunovion Pharmaceuticals Inc.-Product Pipeline Review-2015

Sunovion Pharmaceuticals Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06922CDB
  • |
  • Pages: 52
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sunovion Pharmaceuticals Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Sunovion Pharmaceuticals Inc.-Product Pipeline Review-2015', provides an overview of the Sunovion Pharmaceuticals Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sunovion Pharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Sunovion Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Sunovion Pharmaceuticals Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Sunovion Pharmaceuticals Inc.'s pipeline products

Reasons To Buy

Evaluate Sunovion Pharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Sunovion Pharmaceuticals Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Sunovion Pharmaceuticals Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Sunovion Pharmaceuticals Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sunovion Pharmaceuticals Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Sunovion Pharmaceuticals Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Sunovion Pharmaceuticals Inc. Snapshot 6

Sunovion Pharmaceuticals Inc. Overview 6

Key Information 6

Key Facts 6

Sunovion Pharmaceuticals Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Sunovion Pharmaceuticals Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Sunovion Pharmaceuticals Inc.-Pipeline Products Glance 14

Sunovion Pharmaceuticals Inc.-Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Sunovion Pharmaceuticals Inc.-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Sunovion Pharmaceuticals Inc.-Early Stage Pipeline Products 18

IND/CTA Filed Products/Combination Treatment Modalities 18

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Sunovion Pharmaceuticals Inc.-Drug Profiles 21

eslicarbazepine acetate 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

dasotraline 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

glycopyrrolate 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

DSP-2230 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

DSP-3748 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SEP-363856 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

SEP-360 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecule 1 for Neuropsychiatric Disorders 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule for Neuropsychiatric Disorders 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

EP-103 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecules for Central Nervous System Disorders 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Sunovion Pharmaceuticals Inc.-Pipeline Analysis 37

Sunovion Pharmaceuticals Inc.-Pipeline Products by Target 37

Sunovion Pharmaceuticals Inc.-Pipeline Products by Route of Administration 38

Sunovion Pharmaceuticals Inc.-Pipeline Products by Molecule Type 39

Sunovion Pharmaceuticals Inc.-Pipeline Products by Mechanism of Action 40

Sunovion Pharmaceuticals Inc.-Recent Pipeline Updates 42

Sunovion Pharmaceuticals Inc.-Dormant Projects 48

Sunovion Pharmaceuticals Inc.-Discontinued Pipeline Products 49

Discontinued Pipeline Product Profiles 49

dasotraline 49

DSP-1053 49

DSP-8658 49

SEP-228432 49

tecastemizole 49

Sunovion Pharmaceuticals Inc.-Locations And Subsidiaries 50

Head Office 50

Other Locations & Subsidiaries 50

Appendix 51

Methodology 51

Coverage 51

Secondary Research 51

Primary Research 51

Expert Panel Validation 51

Contact Us 51

Disclaimer 52

List of Tables

Sunovion Pharmaceuticals Inc., Key Information 6

Sunovion Pharmaceuticals Inc., Key Facts 6

Sunovion Pharmaceuticals Inc.-Pipeline by Indication, 2015 9

Sunovion Pharmaceuticals Inc.-Pipeline by Stage of Development, 2015 10

Sunovion Pharmaceuticals Inc.-Monotherapy Products in Pipeline, 2015 11

Sunovion Pharmaceuticals Inc.-Partnered Products in Pipeline, 2015 12

Sunovion Pharmaceuticals Inc.-Partnered Products/ Combination Treatment Modalities, 2015 13

Sunovion Pharmaceuticals Inc.-Pre-Registration, 2015 14

Sunovion Pharmaceuticals Inc.-Phase III, 2015 15

Sunovion Pharmaceuticals Inc.-Phase II, 2015 16

Sunovion Pharmaceuticals Inc.-Phase I, 2015 17

Sunovion Pharmaceuticals Inc.-IND/CTA Filed, 2015 18

Sunovion Pharmaceuticals Inc.-Preclinical, 2015 19

Sunovion Pharmaceuticals Inc.-Discovery, 2015 20

Sunovion Pharmaceuticals Inc.-Pipeline by Target, 2015 37

Sunovion Pharmaceuticals Inc.-Pipeline by Route of Administration, 2015 38

Sunovion Pharmaceuticals Inc.-Pipeline by Molecule Type, 2015 39

Sunovion Pharmaceuticals Inc.-Pipeline Products by Mechanism of Action, 2015 41

Sunovion Pharmaceuticals Inc.-Recent Pipeline Updates, 2015 42

Sunovion Pharmaceuticals Inc.-Dormant Developmental Projects,2015 48

Sunovion Pharmaceuticals Inc.-Discontinued Pipeline Products, 2015 49

Sunovion Pharmaceuticals Inc., Other Locations 50

Sunovion Pharmaceuticals Inc., Subsidiaries 50

List of Figures

Sunovion Pharmaceuticals Inc.-Pipeline by Top 10 Indication, 2015 8

Sunovion Pharmaceuticals Inc.-Pipeline by Stage of Development, 2015 10

Sunovion Pharmaceuticals Inc.-Monotherapy Products in Pipeline, 2015 11

Sunovion Pharmaceuticals Inc.-Partnered Products in Pipeline, 2015 12

Sunovion Pharmaceuticals Inc.-Pipeline by Top 10 Target, 2015 37

Sunovion Pharmaceuticals Inc.-Pipeline by Top 10 Route of Administration, 2015 38

Sunovion Pharmaceuticals Inc.-Pipeline by Top 10 Molecule Type, 2015 39

Sunovion Pharmaceuticals Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Sunovion Pharmaceuticals Inc.; Sunovion Pharmaceuticals Inc. - Key Therapeutics; Sunovion Pharmaceuticals Inc. - Pipeline Overview and Promising Molecules; Sunovion Pharmaceuticals Inc. - News; Sunovion Pharmaceuticals Inc. - Latest Updates; Sunovion Pharmaceuticals Inc. - Pipeline; Sunovion Pharmaceuticals Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102135
Site License
USD 3000 INR 204270
Corporate User License
USD 4500 INR 306405



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]